As a guest user you are not logged in or recognized by your IP address. You have
access to the Front Matter, Abstracts, Author Index, Subject Index and the full
text of Open Access publications.
With decades of research completed, rAAV-based gene therapies for muscle diseases such as DMD have finally progressed to clinical trials. Multiple approaches, such as gene replacement with mini-dystrophin, gene correction by exon skipping, and reducing chronic inflammation, show promise for the future. Obstacles encountered during human trials have led to novel strategies, including the generation of rAAV pseudo-types, the construction of modified muscle specific promoters, and targeted capsid modifications.
This website uses cookies
We use cookies to provide you with the best possible experience. They also allow us to analyze user behavior in order to constantly improve the website for you. Info about the privacy policy of IOS Press.
This website uses cookies
We use cookies to provide you with the best possible experience. They also allow us to analyze user behavior in order to constantly improve the website for you. Info about the privacy policy of IOS Press.